1-phenyl-8-[[4-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one | 473528-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-phenyl-8-[[4-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one
• 英文别名: 1-phenyl-8-[[4-(1,2,3,4-tetrahydronaphthalen-1-yloxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one
• CAS: 473528-90-4
• 化学式: C₃₀H₃₃N₃O₂
• 分子量: 467.611
• InChiKey: YGGAATJMGWRVKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,2,3,4-四氢-1-萘酚 、 对羟基苯甲醛 在 三丁基膦 、 三乙酰氧基硼氢化钠 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 1,2-二氯乙烷 、 苯 为溶剂， 反应 38.0h， 生成 1-phenyl-8-[[4-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-4-one
  参考文献：
  名称：

  1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS

  摘要：

  公开号：

  EP1392687B1

文献信息

• 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
  申请人：——

  公开号：US20030109539A1

  公开（公告）日：2003-06-12

  The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula 1 wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

  本发明涉及一种新颖的一舁3，8-三氮杂螺[4.5]癸烷-4-酮衍生物，其一般式如下： 1 其中所有变量如本文所定义，在治疗由ORL-1 G蛋白偶联受体介导的疾病和症状中有用。更具体地，本发明的化合物在治疗焦虑、抑郁、物质滥用、神经病痛、急性疼痛、偏头痛、哮喘、咳嗽和改善认知方面有用。
• [EN] 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS<br/>[FR] DERIVES DE 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE UTILES DANS LE TRAITEMENT DE TROUBLES INDUITS PAR LE RECEPTEUR ORL-1
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2002083673A1

  公开（公告）日：2002-10-24

  The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

  本发明涉及一种新型的1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式中所有变量如本文所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。更具体地，本发明的化合物可用于治疗焦虑、抑郁、物质滥用、神经病性疼痛、急性疼痛、偏头痛、哮喘、咳嗽以及改善认知能力的疾病和症状。
• 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders
  申请人：Jordan Alfonzo

  公开号：US20050004154A1

  公开（公告）日：2005-01-06

  The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

  本发明涉及一种新型1,3,8-三氮杂螺[4.5]癸酮衍生物，其通式如下： 其中所有变量均如本文所定义，适用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。更具体地，本发明的化合物适用于治疗焦虑、抑郁、物质滥用、神经病性疼痛、急性疼痛、偏头痛、哮喘、咳嗽和改善认知功能的疾病和症状。
• 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
  申请人：Jordan Alfonzo

  公开号：US20060178390A1

  公开（公告）日：2006-08-10

  The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

  本发明涉及新型1,3,8-三氮杂螺[4.5]癸酮衍生物，其一般式如下：其中所有变量的定义如本文所述，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和病症。更具体地说，本发明的化合物可用于治疗焦虑、抑郁、物质滥用、神经病性疼痛、急性疼痛、偏头痛、哮喘、咳嗽以及改善认知能力的疾病和病症。
• 1,3,8-Triazaspiro&lsqb;4.5&rsqb;decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06777421B2

  公开（公告）日：2004-08-17

  The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

  本发明涉及新的1,3,8-三氮杂螺[4.5]癸酮衍生物，其一般式中所有变量如所定义，可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和病症。更具体地说，本发明的化合物可用于治疗焦虑、抑郁、物质滥用、神经病性疼痛、急性疼痛、偏头痛、哮喘、咳嗽和改善认知功能的疾病和病症。